- Home
- IMCR vs DSL Comparison
IMCR vs DSL Comparison
Compare IMCR & DSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- DSL
- Stock Information
- Founded
- IMCR 2008
- DSL 2013
- Country
- IMCR United Kingdom
- DSL United States
- Employees
- IMCR N/A
- DSL N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- DSL Trusts Except Educational Religious and Charitable
- Sector
- IMCR Health Care
- DSL Finance
- Exchange
- IMCR Nasdaq
- DSL Nasdaq
- Market Cap
- IMCR 1.5B
- DSL 1.3B
- IPO Year
- IMCR 2021
- DSL N/A
- Fundamental
- Price
- IMCR $36.60
- DSL $12.30
- Analyst Decision
- IMCR Buy
- DSL
- Analyst Count
- IMCR 10
- DSL 0
- Target Price
- IMCR $58.13
- DSL N/A
- AVG Volume (30 Days)
- IMCR 440.3K
- DSL 298.1K
- Earning Date
- IMCR 05-07-2025
- DSL 01-01-0001
- Dividend Yield
- IMCR N/A
- DSL 10.73%
- EPS Growth
- IMCR N/A
- DSL N/A
- EPS
- IMCR N/A
- DSL N/A
- Revenue
- IMCR $333,581,000.00
- DSL N/A
- Revenue This Year
- IMCR $25.96
- DSL N/A
- Revenue Next Year
- IMCR $8.06
- DSL N/A
- P/E Ratio
- IMCR N/A
- DSL N/A
- Revenue Growth
- IMCR 25.75
- DSL N/A
- 52 Week Low
- IMCR $23.15
- DSL $10.58
- 52 Week High
- IMCR $49.05
- DSL $13.24
- Technical
- Relative Strength Index (RSI)
- IMCR 71.46
- DSL 60.60
- Support Level
- IMCR $31.14
- DSL $11.90
- Resistance Level
- IMCR $33.30
- DSL $12.20
- Average True Range (ATR)
- IMCR 1.94
- DSL 0.11
- MACD
- IMCR 0.57
- DSL 0.02
- Stochastic Oscillator
- IMCR 96.12
- DSL 93.02
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.